No Data Yet
JPMorgan warns that "extreme crowding" in speculative growth stocks like Broadcom, which has fallen over 21%, creates high risk for a sharp market reversal.
Astellas and Pfizer's Phase 3 trial for PADCEV plus Keytruda shows significant survival improvement for muscle-invasive bladder cancer, meeting its primary endpoints.
CorMedix projects 613% sales growth for 2025, positioning it as a potentially stronger investment than Puma Biotechnology, whose stock has rallied 66.7% on weaker fundamentals.
Morgan Stanley lowered its price target on Pfizer (PFE) to $28 from $32, even as the company reported positive Phase 3 results for its TUKYSA cancer drug which extended patient survival by over eight months.
Pfizer signed a $2.1 billion licensing deal with China's YaoPharma to develop a GLP-1 weight loss pill, marking a significant investment to capture a share of the growing obesity treatment market.
Pharmaceutical M&A deal value increased 31% year-over-year to $179.6 billion in 2025, driven by a series of mega-deals in the second half of the year as companies seek to replenish drug pipelines.
The Dow Jones Industrial Average fell 0.62% and the S&P 500 dropped 0.24% on December 16 following a surprise jobs report, while the Nasdaq Composite rose 0.23% led by Nvidia.
Analysis of the iShares Russell 2000 Growth ETF (IWO) is set against a backdrop of broad market uncertainty, as investors weigh mixed economic signals against long-term structural growth trends. There are no specific fundamental drivers currently moving the ETF.
The U.S. unemployment rate rose to a four-year high of 4.6% in November, signaling a weakening labor market. Concurrently, Pfizer lowered its 2026 profit forecast, citing declining COVID-related revenue, which prompted a drop in its stock price.
Ardent Health (ARDT) stock plummeted over 33% following the disclosure of a $97 million accounting adjustment related to revenue and liability reserves. The event has triggered a law firm investigation into whether leadership concealed material weaknesses in internal controls, leading to significant investor losses.
Guardant Health is partnering with Trial Library to integrate its precision oncology diagnostics with an AI-powered platform, aiming to broaden patient access to U.S. cancer clinical trials and streamline enrollment.
A recent analysis by Simply Wall St suggests that Viatris (VTRS) is significantly undervalued based on key financial metrics, despite its volatile stock performance and a year-to-date decline. Investor sentiment remains cautious amid questions over the company’s long-term strategy.
Institutional investors are increasing their positions in mining and precious metals companies, signaling a bullish outlook for the sector. This comes as firms like Mesabi Trust and Buenaventura Mining see significant new investment and positive analyst ratings, respectively, while the broader market faces mixed economic signals.
Zions Bancorporation (ZION) faces a challenging outlook with projected declines in net interest income, reflecting a broader market trend where traditional banks are underperforming compared to the rapidly expanding non-bank financial sector. This divergence highlights a potential systemic shift in capital allocation and risk.
Pfizer (PFE) shares fell approximately 5% after the company reduced its 2026 earnings and revenue guidance, citing declining demand for its COVID-19 products and upcoming patent expirations. The company is actively shifting its focus toward innovation and acquisitions to build its future drug pipeline.
nVent Electric plc has approved a 5% increase to its quarterly cash dividend, signaling confidence in its financial health and commitment to shareholder returns amidst a broader trend of mature companies boosting payouts.
Pentair has announced a significant capital return program, featuring an 8% increase in its quarterly dividend and a new $1 billion share repurchase authorization. This move signals management confidence in the company's financial stability and future cash flows.
Starbucks has declared a new quarterly dividend, signaling financial confidence despite its stock trading below recent highs and mixed foot traffic data from Q3 2025. This move occurs as the company leverages promotional events to drive customer visits.
Flutter Entertainment faces dual pressures from a UK tax hike on gaming and a strategic board appointment. The company has appointed Pfizer's Sally Susman, a move seen as an effort to navigate the increasingly complex regulatory landscape while mitigating financial headwinds.
JPMorgan Chase & Co. has formally declared a routine dividend for its Series CC preferred stock, a standard financial procedure with minimal market impact. The action confirms the firm's adherence to its obligations for fixed-income investors.